Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Precision BioSciences, Inc. (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
Prendio-BioProcure Launches New Generative AI, Analytics, and Workflow Automation Capabilities Enhancing its Market Leading Life Sciences P2P Technology Solution [Yahoo! Finance]